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ABSTRACT: Melanoma remains the leading cause of skin cancer–related deaths. Surgical resection and adjuvant therapies can result in
disease-free intervals for stage III and stage IV disease; however, recurrence is common. Understanding microRNA (miR) dynamics following
surgical resection of melanomas is critical to accurately interpret miR changes suggestive of melanoma recurrence. Plasma of 6 patients with
stage III (n = 2) and stage IV (n = 4) melanoma was evaluated using the NanoString platform to determine pre- and postsurgical miR expression
profiles, enabling analysis of more than 800 miRs simultaneously in 12 samples. Principal component analysis detected underlying patterns of
miR expression between pre- vs postsurgical patients. Group A contained 3 of 4 patients with stage IV disease (pre- and postsurgical samples)
and 2 patients with stage III disease (postsurgical samples only). The corresponding preoperative samples to both individuals with stage III
disease were contained in group B along with 1 individual with stage IV disease (pre- and postsurgical samples). Group A was distinguished
from group B by statistically significant analysis of variance changes in miR expression (P < .0001). This analysis revealed that group A vs
group B had downregulation of let-7b-5p, miR-520f, miR-720, miR-4454, miR-21-5p, miR-22-3p, miR-151a-3p, miR-378e, and miR-1283 and
upregulation of miR-126-3p, miR-223-3p, miR-451a, let-7a-5p, let-7g-5p, miR-15b-5p, miR-16-5p, miR-20a-5p, miR-20b-5p, miR-23a-3p,
miR-26a-5p, miR-106a-5p, miR-17-5p, miR-130a-3p, miR-142-3p, miR-150-5p, miR-191-5p, miR-199a-3p, miR-199b-3p, and miR-1976.
Changes in miR expression were not readily evident in individuals with distant metastatic disease (stage IV) as these individuals may have
prolonged inflammatory responses. Thus, inflammatory-driven miRs coinciding with tumor-derived miRs can blunt anticipated changes in
expression profiles following surgical resection.
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Introduction

Melanoma remains the leading cause of skin cancer–related
deaths, and an estimated 76 380 individuals will be diagnosed
in the United States in 2016.1 Early-stage disease has a favorable prognosis with surgical intervention as the mainstay of
treatment. The survival rate of individuals with stage I and
stage II disease is 53% to 97%, whereas involvement of regional
lymph nodes (stage III) results in a 5-year survival of 40% to
78%.2 Not surprisingly, distant metastatic disease has the worst
prognosis with a survival rate of just 33% to 62%.2 Adjuvant
therapies with targeted molecular and immunotherapies have
been investigated in individuals with locally advanced disease;
however, recurrence rates are high.3 Eggermont et al4 found
that treatment of stage III melanoma with the anti-Cytotoxic
T-Lymphocyte Associated Protein 4 (CTLA-4) drug, ipilimumab, resulted in a recurrence-free survival of 46.5% at
3 years. Unfortunately, in the setting of metastatic disease,

National Institutes of Health (NIH) T32 CA090223 (to W.E.C.), and K24 CA093670
(to W.E.C.), and NLM grant T15LM011270 (to Z.B.A).
Declaration of conflicting interests: The author(s) declared no potential
conflicts of interest with respect to the research, authorship, and/or publication of this article.
CORRESPONDING AUTHOR: William E Carson III, Department of Surgery, The Ohio
State University, N924 Doan Hall 410 W, 10th Ave, Columbus, OH 43228, USA.
Email: William.Carson@osumc.edu

many individuals with a primary therapeutic response to
immune-based agents will often develop recurrence despite
initial disappearance of most or all of their disease.5
MicroRNAs (miRs) consist of 19 to 22 nucleotides, noncoding RNA molecules present within all cells. MicroRNAs
target complementary segments on the 3′ untranslated region
of messenger RNA and result in silencing of translation. More
than 800 different miRs are present within cells, and the
expression of miRs differs across tissues and disease processes.
Dysregulated miRs are involved in several key cellular pathways responsible for malignant progression including cellular
invasion, migration, proliferation, angiogenesis, replicative
immortality, immune evasion, and avoidance of senescence and
apoptosis.6 Consequently, miRs have been investigated in various malignancies including melanoma.7 MicroRNA dysregulation has been found across different stages of melanoma and
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has been implicated as a biomarker with potential diagnostic
and prognostic usefulness.8 Investigation into its usefulness for
prediction of recurrence has also been studied.9
Understanding miR dynamics following surgical resection
of melanoma is incompletely understood yet is necessary to
accurately interpret miR patterns suggestive of recurrence.
MiR-210 has been suggested as a marker of early metastatic
recurrence in melanoma.10 However, evaluation of a single miR
carries the possibility of overlooking potentially meaningful
candidates; thus, global investigation of the miR transcriptome
is more useful. Ferracin et al11 have used microarray and small
RNA sequencing techniques for postoperative analysis of
serum and plasma melanoma patient samples. They found dysregulation of miR-181a-5p and miR-320a following surgical
resection. However, staging of melanomas in the aforementioned study was not specified. Modern approaches such as
NanoString allow for analysis of the miR transcriptome yet
require lower starting amounts of RNA and have lower associated costs compared with microarray.12 Thus, NanoString is
well suited for noninvasive detection of miRs using plasma
blood samples where RNA quantities are often miniscule.
Herein, we perform an exploratory study to evaluate the potential usefulness of miRs in plasma samples of metastatic melanoma following surgical resection. This work highlights the
similarities of neoplastic and inflammatory-related miRs,
which may act as a confounding variable in the interpretation
of plasma miR studies of metastatic melanoma. Thus, future
studies will need to be carefully constructed to potentially minimize this possibility.

Methods
Blood samples
Six patients undergoing surgical resection for malignant melanoma with metastatic progression to regional lymph node
basins or distant metastatic sites were selected. These patients
were tested between 2013 and 2015 at The Ohio State
University Wexner Medical Center under the auspices of institutional review board protocol No. 1999C0348. Peripheral
venous blood collection was performed in EDTA collection
tubes prior to surgical therapy and on postoperative follow-up
to 3 weeks after surgery. Peripheral blood samples were centrifuged at 1700 rpm for 11 minutes. The plasma layer was isolated and stored at −80°C.

Isolation of RNA
RNA isolation was carried out using 200 µL of plasma samples
with the miRNeasy mini kit (Qiagen, Hilden, Germany)
according to the manufacturer’s recommendations. The addition of 3 miR spike-ins with known concentrations was used as
loading controls. Additional RNA purification was performed
using Amicon (Millipore, Billerica, Massachusetts) 0.5-mL
3-kDa column as per the manufacturer’s recommendations.
Isolated RNA was stored at −80°C.

NanoString
Three microliters of isolated RNA was loaded onto
NanoString nCounter (NanoString Technologies, Seattle,
Washington) platform, and miR quantification was carried
out as previously described.13 Briefly, miRs were ligated with
DNA tags to normalize melting temperatures and provide
unique identification of each miR. Excess tags were removed,
and a panel of capture and reporter probes containing unique
fluorescent signals corresponding to individual miRs were
hybridized at 64°C for 18 hours. Immobilization of hybridized probes onto a streptavidin-coated cartridge was performed using nCounter Prep Station (NanoString
Technologies). The fluorescence of each hybridized miR was
measured by an nCounter Digital analyzer (NanoString
Technologies) with a high-density scan containing 600 fields
of view. The investigation included 5 negative and 5 positive
controls as well as 5 housekeeping genes.

Data analysis
To control for technology-based experimental error, technical
normalization was applied to the raw expression data of 800
miRs before log transformation. Technical normalization controls for performance-based experimental error, and it is applied
to the raw data by the NanoString company. We cannot independently verify the algorithm used in the technical normalization. However, it is standard practice and advised by the
company to utilize technical normalized data rather than the
raw expression. No miR filtering was applied. Using JMP 10
software, variables with highest variance were determined
using the principal component analysis (PCA).

Results

Plasma miR expression of 6 patients undergoing surgical
resection for melanoma was measured preoperatively and
postoperatively using a NanoString platform. Two patients
were diagnosed with stage III disease (patients 2, 3), whereas
the remaining 4 patients had stage IV disease (patients 1, 4, 5,
6; Table 1). Notably, standard analysis (t test) of pre- and postsurgical miR expression data did not reveal any statistically
significant changes in miR expression. Consequently, PCA
was used in an exploratory manner to identify potentially
meaningful associations. This approach mathematically transforms a number of possibly correlated variables into a smaller
number of uncorrelated variables termed principal components.
PCA reduces a complex data set to a limited quantity of new
variables (components) according to variation within the data
set. The variable with the greatest variation is deemed the
principle component. PCA is an exploratory analysis method
that emphasizes variation to bring out strong patterns in complex data sets by reducing their dimensionality. Accordingly,
using NanoString miR expression data from pre- and postsurgical melanoma samples, PCA allows for categorization of
correlated patterns of miR expression variation (ie, principal
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Six patients undergoing surgical resection of melanoma lesions were classified according to pathologic stage and grouping on PCA before and after surgical resection.
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components) and identification of miRs exhibiting variation
across the identified components.
Two categories (groups A and B) became evident when
analyzed through PCA (Figure 1). Two individuals (patients

Figure 1. Principal component analysis of plasma miR expression
following resection of melanoma.

MicroRNA (miR) expression was measured in 6 patients preoperatively
() and postoperatively () using the NanoString platform. Relationship
of plasma miR expression before and after surgical resection was
investigated using principal component analysis according to
components that could explain the largest variation within the data set.
Components 1 and 2 account for the largest variation and were used for
generation of the score plot.

2 and 3) did have preoperative and postoperative samples in
separate groups as defined by PCA. Both of these patients
had stage IIIc disease. However, this pattern was not observed
in the remaining individuals with stage IV disease. Three of
4 individuals with stage IV disease had both preoperative
and postoperative samples in group A, whereas the remaining patient had both samples in group B. Overall, individuals
with high variability in miR patterns following surgical
resection corresponded to individuals with IIIc disease,
whereas others with distant metastatic disease (stage IV ) had
less variability.
Principal component analysis was performed using multiple
stratifications. The dominant stratification (component 1) contained the most variability among the samples (74.3%).
Additional groupings accounted for some variation but to a
lesser extent (Figure 2). Component 2 contained the second
highest variability among the sample set followed by the
remaining components in a sequentially lower degree. Overall,
the majority of variability within the data set was explained by
component 1.
Individual miR expression between groups A and B was
analyzed using analysis of variance (ANOVA), and several
miRs were differentially expressed to a significant degree (P <
.0001). This analysis revealed that group A vs group B had
downregulation of let-7b-5p, miR-520f, miR-720, miR4454, miR-21-5p, miR-22-3p, miR-151a-3p, miR-378e, and
miR-1283 and upregulation of miR-126-3p, miR-223-3p,
miR-451a, let-7a-5p, let-7g-5p miR-15b-5p, miR-16-5p,
miR-20a-5p, miR-20b-5p, miR-23a-3p, miR-26a-5p, miR106a-5p, miR-17-5p, miR-130a-3p, miR-142-3p, miR150-5p, miR-191-5p, miR-199a-3p, miR-199b-3p, and
miR-1976 (Table 2).

Figure 2. Components contributing to total variation in principal component analysis.

Principal component analysis of microRNA expression in pre- and postsurgical melanoma samples revealed that several components contribute to
overall variation within the data set. Component 1 contributes to the largest variation.
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Table 2. Differential microRNA expression between groups A and B in principal component analysis.
MicroRNA

Group A average

Group B average

Fold change

hsa-miR-1976

1.509

3.242

2.148

hsa-miR-191-5p

1.639

2.867

1.750

hsa-miR-150-5p

1.498

2.560

1.709

hsa-let-7a-5p

1.832

3.112

1.699

hsa-miR-126-3p

2.147

3.422

1.593

hsa-miR-16-5p

1.924

3.002

1.561

hsa-miR-20a-5p + hsa-miR-20b-5p

2.059

2.942

1.429

hsa-miR-451a

2.827

3.941

1.394

hsa-miR-106a-5p + hsa-miR-17-5p

2.130

2.940

1.380

hsa-miR-142-3p

2.386

3.286

1.377

hsa-miR-15b-5p

2.327

3.039

1.306

hsa-let-7g-5p

2.532

3.223

1.273

hsa-miR-199a-5p

2.048

2.535

1.238

hsa-miR-223-3p

3.536

4.146

1.173

hsa-miR-15a-5p

2.139

2.461

1.150

hsa-miR-23a-3p

2.830

3.112

1.100

hsa-miR-130a-3p

2.774

2.959

1.067

hsa-miR-4454

4.273

4.049

0.948

hsa-miR-21-5p

3.198

2.968

0.928

hsa-let-7b-5p

3.477

3.085

0.887

hsa-let-7c

2.216

1.781

0.803

hsa-miR-199b-5p

1.237

0.961

0.777

hsa-miR-378e

3.383

2.613

0.772

hsa-miR-720

3.668

2.644

0.721

hsa-miR-1283

3.557

2.503

0.704

Differences in individual microRNA expression between groups A and B based on principal component analysis.

Discussion

Exploratory evaluation of miR profiles in plasma of melanoma
patients before and after surgery did not yield any significant
miRs (data not shown). However, PCA was able to distinguish
the 2 groups across all plasma samples, group A and group B, as
shown in Figure 1. Through the analysis of the miRs that comprise component 1 of the PCA analysis, we determined that
group A vs group B had downregulation of let-7b-5p, miR-520f,
miR-720, miR-4454, miR-21-5p, miR-22-3p, miR-151a-3p,
miR-378e, and miR-1283 and upregulation of miR-126-3p,
miR-223-3p, miR-451a, let-7a-5p, let-7g-5p miR-15b-5p,
miR-16-5p, miR-20a-5p, miR-20b-5p, miR-23a-3p, miR26a-5p, miR-106a-5p, miR-17-5p, miR-130a-3p, miR-142-3p,
miR-150-5p, miR-191-5p, miR-199a-3p, miR-199b-3p, and

miR-1976 (P < .0001 using ANOVA). Given the absence of
technical replicates and normalized controls, this form of data
driven cohort discovery seemed a sensible approach to elucidate
potential underlying relationships.
Several of the 5 most differentially expressed miRs in this
study have been previously reported in the setting of melanoma. Both miR-150 overexpression and downregulation have
been described in malignant melanoma and may exert effects
on several pathways such as cellular proliferation through regulation of v-myb avian myeloblastosis viral oncogene homolog.14
MiR-126 is downregulated in malignant melanoma relative to
primary melanoma cells and leads to increased chemotaxis and
cellular proliferation in A375M melanoma cells transfected
with anti-miR-126.15 This effect is mediated in part through
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reduced inhibition of miR-126–targeted metalloproteases: a
disintegrin and metalloprotease domain 9 and matrix metalloprotease-7.15 Let-7a is downregulated in malignant melanoma
relative to primary melanoma cell lines, which results in induction of integrin β3 and increased invasive capacity as assessed
by Boyden Chamber invasion assays.16 MiR-191 downregulation has been described in association with melanoma patients
containing BRAF mutations.17 Notably, miR-1976 was the
most differentially expressed miR; however, it has not been
previously described in the setting of malignant melanoma.
Among the downregulated miRs, several turned out to be
known oncomiRs, including miR-21. MiR-21 upregulation
in malignant melanoma relative to benign nevi has previously
been shown.7 MiR-21 upregulation in melanoma leads to
downregulation of tissue inhibitor of metalloprotease-3,
which in turn leads to increased cellular invasion, thereby
suggesting a mechanism of miR-21–mediated tumor progression.8 Furthermore, miR-720 has previously been shown
to be upregulated in cutaneous melanoma compare with
benign melanocytic nevi.18
Conversely, there was upregulation of several important
miRs between group A vs group B. Several of these miRs are
tumor suppressors that are downregulated in malignant melanoma and might be expected to increase following surgical
excision. For instance, miR-26a-5p downregulation has been
reported in primary cutaneous melanoma tissue relative to nevi
and is responsible for inhibition of alpha-type platelet-derived
growth factor receptor that can lead to increased cellular
proliferation.19,20
Unlike patients with stage IIIc disease, clear differences in
miR expression were not observed in plasma samples of preand postsurgical patients with distant metastatic (stage IV )
disease. Greater degrees of inflammation have been associated with later stages of melanoma.21 Bernardes et al21
revealed that increased proinflammatory markers such as
C-reactive protein, γ-glutamyl transpeptidase and malondialdehyde (MDA) were present in later stages of melanoma.
In addition, high levels of MDA persist following surgical
resection and suggest a sustained inflammatory response.21
As such, inflammatory miRs associated with postoperative
wound healing and remodeling may blunt large differences
across the pre- and postsurgical samples in melanoma
patients. Indeed, the oncomiR miR-21 can be induced by
interleukin 6, an important mediator in wound healing.22,23
Furthermore, angiogenesis is an important component of
wound healing, and miRs can regulate several proteins
involved with both angiogenesis and tumor progression,
including vascular endothelial growth factor (VEGF) (miR20a) and Sprouty-related EVH1 domain-containing protein
1 (SPRED1) (miR-126).24,25 Thus, miRs implicated in oncogenesis may also participate in the postoperative inflammatory response, thereby blunting anticipated changes following
surgical excision for distant metastatic lesions.
Fitting with this presumption, 1 patient with stage IV
disease who underwent a lymphadenectomy had cellulitis

postoperatively (patient 1) and did not have a major reduction
in global miR expression. Tili et al26 report upregulation of
miR-155 not only in solid and hematologic malignancies but
also during the inflammatory response, particularly during proliferation of lymphocytes where miR-155 can in turn regulate
expansion of granulocytes and monocytes, T-cell differentiation, and B-cell maturation. Igglezou et al27 similarly found
transient upregulation of miR-155 in postoperative blood samples following mastectomy. Our results suggest postoperative
blood draws within weeks of surgical resection for miR analysis
may not be suitable for proper evaluation of tumor-driven miR
changes in stage IV patients, given the overlap of miRs involved
with inflammation and tumor progression.
There are some notable limitations to this study. First, a limited patient sample of pre- and postsurgical patients was studied due to the difficulty in obtaining consent from patients
who were embarking on surgery with the hopes of achieving no
evidence of disease. This was an exploratory study, and ultimately, greater numbers of patients will be needed in future
studies to adequately evaluate these findings as well as any
potential differences. Second, nonsurgical controls were absent;
however, this was acceptable given the intent to address changes
within miR profiles between patients before and after surgery.
These factors limit the power of this analysis and strength of
our conclusions. The PCA analysis used herein identified miRs
with a high degree of variance. Additional work is warranted to
better understand changes in miR expression after surgery and
validate the significance of the miRs herein.

Conclusions

We suggest miR analysis of plasma in melanoma patients is
feasible to analyze miR dynamics following surgical excision.
However, care should be exercised with respect to the design
and timing of future postoperative plasma studies as analyses in
close temporal proximity to surgical excision may obscure differences in miR trends. Ideally, future studies will incorporate
additional postsurgical blood draws at different time points to
more comprehensively analyze these trends. Likewise, analysis
of distant metastatic samples does not appear to have large
variations in miR patterns following surgical resection, which
may be attributed, in part, to a sustained inflammatory response
postoperatively. Future studies may specifically tailor their
design to include individuals limited to locoregional disease
when performing plasma-based approaches and consider the
use of tissue-based approaches for those with distant metastatic disease to potentially avoid this discrepancy. Ultimately,
further characterization of the impact of staging and temporal
response on postsurgical inflammation is necessary to accurately understand plasma miR dynamics in melanoma.
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